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Two Different Doses of Intravitreal Bevacizumab  
for Treatment of Choroidal Neovascularization 
Associated with Age-related Macular Degeneration 
 Mehdi Modarreszadeh, MD; Masood Naseripour, MD; Khalil Ghasemi-Falavarjani, MD 
Aminollah Nikeghbali, MD; Masih Hashemi, MD; Mohammad-Mehdi Parvaresh, MD   
Eye Research Center, Rasoul Akram Hospital, Iran Medical University, Tehran, Iran 
Purpose: To compare the efficacy and safety of 1.25 mg versus 2.5 mg intravitreal beva-
cizumab (IVB) for treatment of choroidal neovascularization (CNV) associated with age-
related macular degeneration (AMD). 
Methods: In this randomized clinical trial, consecutive patients with active CNV 
associated with AMD received 1.25 mg or 2.5 mg IVB. Best corrected visual acuity 
(BCVA), foveal thickness and side effects of therapy were evaluated one and three 
months after intervention.  
Results: Overall 86 subjects were enrolled and completed the scheduled follow-up. Forty 
seven and 39 patients received 1.25 and 2.5 mg IVB respectively. The study groups were 
balanced in terms of baseline characteristics such as age, BCVA and foveal thickness. 
Mean improvement in BCVA was 0.06±0.3 logMAR in the 1.25 mg group and 0.07±0.34 
logMAR in the 2.5 mg group (P=0.9). Mean decrease in foveal thickness was 49±36 µm 
in the 1.25 mg group and 65±31µm in the 2.5 mg group (P=0.6). Three cases of vitreous 
reaction and one case of massive subretinal hemorrhage were observed in the 2.5 mg 
group. 
Conclusion: Double dose (2.5 mg) IVB does not seem to be more effective than regular 
dose (1.25 mg) injections for treatment of CNV due to AMD and may lead to more 
complications.  
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INTRODUCTION  
 
Age-related macular degeneration (AMD) is  
the leading cause of irreversible visual loss in 
the elderly; severe visual loss in such cases is 
most often due to choroidal neovascularization 
(CNV).1-4 Increased expression of vascular en-
dothelial growth factor (VEGF) has been shown 
in human eyes with neovascular AMD.5,6 In 
recent years there has been an increasing trend 
toward intravitreal injection of VEGF inhibitors 
for treatment of exudative maculopathy and 
the outcomes have been relatively favorable as 
compared to other treatment modalities.7-15  
Currently, two closely related anti-VEGF 
agents, bevacizumab and ranibizumab (both 
from Genentech Inc., South San Francisco, CA, 
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AMD. Bevacizumab (Avastin), the full-length 
humanized monoclonal anti-VEGF antibody, 
was approved for treatment of colorectal cancer 
in 2004.12,13 Bevacizumab has been designed for 
intravenous injection; however when injected 
into the vitreous cavity, it has been shown to be 
effective for preventing visual loss and impro-
ving visual acuity in patients with neovascular 
AMD.7-9,16 Ranibizumab, an antibody fragment 
of bevacizumab, received FDA approval for 
intravitreal injection for AMD-associated CNV 
in 2006. Although bevacizumab has not yet 
been approved for this route of administration, 
many ophthalmologists continue to use it ins-
tead of ranibizumab due to much lower price.17 
Despite its widespread use, the “safe and effect-
tive” dose for intravitreal bevacizumab is not 
well established.  
Intravitreal bevacizumab (IVB) was first 
used for treatment of CNV associated with 
AMD by Rosenfeld et al18 who injected a single 
dose of 1.0 mg bevacizumab. Based on phase III 
trial reports on monthly intravitreal injections 
of 0.3 to 0.5 mg ranibizumab and considering 
the fact that the molecular weight of bevacizu-
mab is approximately three times that of rani-
bizumab, the dose of bevacizumab containing 
the same number of molecules would be 0.9 to 
1.5 mg. Considering other factors such as the 
presence of two antigen binding sites on the 
bevacizumab molecule as compared to a single 
site on ranibizumab and that ranibizumab has 
been genetically engineered for increased affi-
nity to VEGF, the authors eventually estimated 
that 1.0 to 1.25 mg of bevacizumab seems to be 
suitable for conducting a dose-response study. 
Thereafter, most authors have used 1.25 mg 
IVB for treatment of neovascular AMD.7-9 Some 
investigators however opted to use higher 
doses hoping to achieve higher efficacy with 
varying results.19-22  
With the paucity of reports comparing 
different doses of IVB, the optimal dose for 
highest efficacy and minimal toxicity is not 
clear. This randomized clinical trial was con-
ducted to compare the outcomes of 1.25 mg vs 
2.5 mg intravitreal bevacizumab in eyes with 
CNV associated with AMD. 
METHODS 
 
This prospective, randomized clinical trial was 
performed on consecutive patients aged 50 or 
more with AMD and active subfoveal CNV of 
any angiographic subtype with best-corrected 
visual acuity (BCVA) of 20/40 to 20/2000 
(equivalent to counting fingers at 2 feet). CNV 
activity was judged according to history of 
recent visual loss, presence of subretinal fluid 
with or without subretinal hemorrhage and/or 
exudates, and obvious leakage on fluorescein 
angiography (FA) 1 week prior to enrollment.  
Exclusion criteria included CNV due to 
disorders other than AMD, vision limiting con-
ditions other than AMD such as diabetic retino-
pathy, recent or old retinal vein occlusion in-
volving the fovea, and any sign of ocular infla-
mmation. Patients were also excluded if they 
had previous intraocular surgery other than 
uncomplicated cataract surgery more than 3 
months before, previous photodynamic thera-
py, history of external beam radiation to the 
skull region and inability to comply with the 
study protocol.  
Ophthalmic examinations included BCVA 
measurement with the Early Treatment of 
Diabetic Retinopathy Study (ETDRS) chart, in-
traocular pressure measurement, slitlamp bio-
microscopy and dilated funduscopy using an 
indirect ophthalmoscope and at the slitlamp 
using a +90 diopters lens. Paraclinical evalua-
tions included FA and optical coherence tomo-
graphy (Stratus III OCT, Carl Zeiss, Dublin, 
California, USA).   
Patients were randomly assigned to receive 
1.25 or 2.5 mg IVB (equivalent to 0.05 and 0.1 
ml of commercially available Avastin, respec-
tively). The injections were performed accor-
ding to a previously described protocol.7 A 
cotton-tipped applicator was placed adjacent to 
the needle and rolled over the injection site 
immediately upon needle withdrawal while 
applying mild pressure for 30 seconds. Indirect 
ophthalmoscopy was then performed to ascer-
tain patency of the central retinal artery. The 
eye was then patched following instillation of 
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were instructed to remain in supine position for 
8 hours and to call the emergency room in case 
of pain or blurred vision.  
All patients were visited 48 hours after IVB 
injection and one week, one month and 3 
months thereafter. One month after each inject-
tion, treatment was repeated in case of persis-
tent subretinal fluid with or without hemorrh-
age, or if leakage was observed on FA. Maxi-
mum numbers of injections for each patient 
was three. OCT was obtained to determine 
foveal thickness at baseline and repeated 1 and 
3 months after the first injection. Outcome mea-
sures included changes in BCVA and foveal 
thickness at 3 months.  
Changes in BCVA were compared within 
each group using paired t-test and between the 
2 groups using Chi-square and t-tests with 
significance level set at 0.05. The Institutional 
Review Board and Ethics Committee of the eye 
research center approved the study and in-




Initially 95 patients had been enrolled in the 
study; however, one patient in the 1.25 mg
group and 8 subjects in the 2.5 mg group  
were lost to follow-up and therefore excluded. 
Eventually, 86 eyes of 86 patients including  
47 and 39 patients in the 1.25 and 2.5 mg IVB 
groups who completed the scheduled follow-
up were analyzed. The 1.25 mg group included 
32 (66.1%) male and 15 (31.9%) female subjects 
with mean age of 73.8±8.5 (range 48-85) years 
and the 2.5 mg group included 26 (66.7%) male 
and 13 (33.3%) female subjects with mean age 
of 71.1±9.2 (range 49-87) years. Baseline patient 
characteristics and outcomes of the study are 
shown in table 1. There was no difference bet-
ween the 2 groups regarding age, sex, baseline 
BCVA and pretreatment foveal thickness.  
Mean increase in BCVA was 0.06±0.3 
logMAR in the 1.25 mg group and 0.07±0.34 
logMAR in the 2.5 mg group (P=0.9). Mean 
decrease in foveal thickness was 49±36 µm in 
the 1.25 mg group and 65±31 µm in the 2.5 mg 
group (P=0.6). Twelve (25.5%) patients in the 
1.25 mg group and 9 (23.1%) patients in the 2.5 
mg group experienced at least 3 lines (15 
letters) of improvement in BCVA (P=0.7). In 
contrast 6 (12.8%) patients in the 1.25 mg group 
and 4 (10.3%) subjects in the 2.5 mg group lost 
more than 3 lines (15 letters) of BCVA (P=0.7).  
 




1.25 mg 2.5 mg 
Male (n)  32 26 
0.8* 
Female (n) 15 13 
Age (years): M±SD 73.8±8.5 71.1±9.2 0.18** 
Baseline BCVA (logMAR): M±SD 1.13± 0.5 1.26±0.46 0.2** 
Baseline foveal thickness (µm): M±SD 325±54 339±62 0.8** 
Third month BCVA (logMAR): M±SD 1.0±0.49 1.1±0.49 0.2** 
Third month foveal thickness (µm): M±SD 276±55 274±50 0.8** 
M, mean; SD, standard deviation; BCVA, best-corrected visual acuity. 
*Chi-square test. **t-test . 
 
 
Mean number of injections was 1.5±0.5 
(range 1-3) in the 1.25 mg group versus 1.8±0.8 
(range 1-3)  in the 2.5 mg group (P=0.07). No 
adverse events were observed in the 1.25 mg 
group; however, 3 cases (7.7%) of intravitreal 
inflammation were observed in the 2.5 mg 
group within 48 hours (Fig. 1). Vitritis was 
associated with decreased visual acuity and 
trace anterior chamber reaction in all 3 cases; 
the grade of vitritis was +3 in one patient and 
+2 in two others. The more severe case was 
treated with oral prednisolone 50 mg daily for 1 
week and topical betamethasone for 3 weeks. 
Intraocular inflammation gradually subsided 
with visual improvement over 1 month in all 3 
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developed acute posterior vitreous detachment 
(PVD) associated with pinpoint peripheral re-
tinal hemorrhages in one case. One patient with 
predominantly classic CNV developed sudden 
visual loss 6 days after 2.5 mg IVB injection due 
to massive subretinal hemorrhage on fundus-
copy (Fig. 2). The patient refused intravitreal 
tissue plasminogen activator and gas injection. 
 
 
Figure 1 (A) Fundus photograph of a patient with choroidal neovascularization associated 
with age-related macular degeneration before injection of intravitreal bevacizumab (IVB).  




Figure 2 Fundus photograph of a patient with 
choroidal neovascularization associated with 
age-related macular degeneration 6 days after 
injection of 2.5 mg bevacizumab. Note the 





The optimal dosage of intravitreal bevacizumab 
has not been clearly established. We found that 
1.25 and 2.5 mg IVB are comparable in terms of 
visual improvement and reduction in macular 
thickness in patients with CNV due to AMD. A 
dose escalating study by Costa et al19 has 
shown progressively higher efficacy for both 
1.5 and 2 mg IVB as compared to 1 mg IVB in 
eyes with CNV secondary to AMD. However, 
Wu et al22 reported similar efficacy for 1.25 and 
1.5 mg intravitreal bevacizumab in 45 patients 
with branch retinal vein occlusion. These stu-
dies were retrospective or data were gathered 
from several centers located in different coun-
tries. To the best of our knowledge, this is the 
only prospective study comparing different 
doses of IVB in the same treatment setting.  
Uveitis has been reported after intravitreal 
injections of both bevacizumab and ranibizu-
mab.23-25 Bakri et al25 reported 4 cases of intra-
ocular inflammation including 2 cases of iritis 
and 2 cases of vitritis following IVB and stre-
ssed the importance of avoiding unnecessary 
treatment for endophthalmitis. Although the 
authors did not mention the dosage, they 
apparently used the usual 1.25 mg dose.  
Adverse effects of IVB have been studied in 
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intravitreal injection of different doses of beva-
cizumab up to 5 mg in the rabbit and reported 
vitreous inflammation only with the 5 mg dos-
age but observed no histological or electro-
retinographic evidence of retinal toxicity. Simi-
larly, Feiner et al27 did not find any abnormali-
ties on photopic or scotopic electroretinograms 
(ERG) and no histological evidence of toxicity 
in rabbit eyes following intravitreal injection of 
1.25 and 2.5 mg bevacizumab. Shahar and co-
workers28 observed full-thickness retinal penet-
ration of the agent following 2.5 mg IVB in 
rabbit eyes but reported no sign of toxicity on 
ERG or visual evoked potential. In the current 
study, we encountered 3 cases (7.7%) of clini-
cally significant inflammation using the same 
dosage. This difference may be in part due to 
differences in the immunologic response in 
human and rabbit eyes. In clinical experiments, 
no inflammation was observed with 2.5 mg 
dosage in some studies,19,20,22 while apparent in 
another study using the 1.25 mg dosage.25 
Studies in which intraocular inflammation have 
not been reported are generally retrospective; 
giving rise to the possibility that occasional 
cases of mild reaction remained unnoticed or 
unreported. Another possible explanation is 
changes in formulation of bevacizumab by the 
manufacturer. However, in an inquiry from 
Genentech technical representatives during the 
American Academy of Ophthalmology meeting 
in November 2007 by one of the authors (MM), 
they denied any change in the formulation of 
bevacizumab up to the time of our study.  
In our series, PVD was observed in 2 pa-
tients in the 2.5 mg group accompanied by 
peripheral pinpoint bleedings in one case. Al-
though PVD was uneventful in both patients, it 
may predispose to retinal detachment. Retinal 
detachment has actually been reported follow-
ing IVB injections.29 We also encountered a 
single dose of large subretinal hemorrhage. It is 
hard to directly attribute the hemorrhage to 
bevacizumab since CNV itself may lead to sub-
retinal hemorrhage at any time. On the other 
hand, it is conceivable that rapid shrinkage of 
CNV following IVB may increase the chance for 
subretinal hemorrhage. This complication has 
previously been reported by Chieh and Fekrat30 
after 1.25 mg IVB.  
Despite limited follow-up, our study has 
the advantages of being prospective and being 
performed at a single center. We found 2.5 mg 
IVB to be equally effective as 1.25 mg but the 
higher dose seems to be associated with more 
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